

Title:

Liver transplant in a receptor with ABO incompatibility: a viable option

Authors:

Alfredo Vivas López , Iago Justo Alonso, Carmelo Loinaz Segurola

DOI: 10.17235/reed.2020.7416/2020

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Vivas López Alfredo, Justo Alonso Iago , Loinaz Segurola Carmelo. Liver transplant in a receptor with ABO incompatibility: a viable option . Rev Esp Enferm Dig 2020. doi: 10.17235/reed.2020.7416/2020.



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Accepted Article

CC 7416

Liver transplant in a receptor with ABO incompatibility: a viable option

Alfredo Vivas López, Iago Justo Alonso, Carmelo Loinaz Seguro.

General surgery Unit. "12 de Octubre" University hospital. Madrid. Spain.

Correspondence author: Alfredo Vivas López. E-mail: alfredovivas7@gmail.com

Keywords: Liver Transplant. Incompatibility. Urgent.

Dear Editor,

We present the case of a 41 year old male with type A blood group and a diagnosis of fulminant liver failure of unknown cause who was admitted to the ICU with severe coagulopathy (INR 6), hyperammonemia (250 $\mu\text{mol/l}$) and grade IV encephalopathy (4 King's criteria and both Clichy's criteria (1)). He also had GCS 8/15 despite TDE-MARS, dialysis and ventilatory support via endotracheal tube due to encephalopathy. He was listed as a status 0 for liver transplant. In the absence of a compatible donor, the patient received an ABO incompatible liver transplant (LT), group O, using the piggy back technique, without any complications. He required transfusion of 5 units of plasma but did not require blood transfusion.

Induction therapy was administered with Rituximab, followed by triple-therapy immunosuppression (prednisone, tacrolimus and mycophenolate), as well as Basiliximab boluses. Anti-A antibodies were serially measured, and he had plasmapheresis or immunoglobuline perfusion on alternating days. There was clinical evidence of humoral rejection despite a non-specific liver biopsy, for which he was treated with three boluses of 1g of steroids. His liver profile and coagulopathy improved slowly and he fully recovered from a neurological standpoint. He was discharged to a regular ward bed and later on, home.

DISCUSSION

ABO incompatible LT (ABOi LT) with standard immunotherapy has traditionally been a relative contraindication for LT due to the high rate of humoral response and complications, leading to graft loss (2). However, in view of organ shortage, several immunosuppressive regimens that reduce anti-A/B antibodies (3) exist, allowing for good results after live-donor ABOi LT. There is scant evidence for this technique in brain-dead donors, let alone in fulminant liver failure (4). There are some successful cases, such as the one here presented, but larger studies are needed to demonstrate the long-term viability of these organs.

REFERENCES

1. McPhail, M.J., Wendon, J.A., Bernal, W. Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. *J Hepatol.* 2010;53(3):492-499. doi:10.1016/j.jhep.2010.03.023
2. Goss, M.B. and Rana, A. (2017). ABO-incompatible liver transplantation: Is it a viable option with modern innovation?. *Clinical Liver Disease*, 10: 124-129. doi:10.1002/cld.673
3. Rummler, S., Bauschke, A., Bärthel, E. *et al.* Current techniques for ABO-incompatible living donor liver transplantation. *World J Transplant.* 2016;6(3):548-555. doi:10.5500/wjt.v6.i3.548
4. Skogsberg, U., Bennet, W. (2019) ABO-Incompatible Liver Transplantation – A Review of the Historical Background and Results, *International Reviews of Immunology*, 38:3, 118-128, DOI: 10.1080/08830185.2019.1601720